The Clinical Consequences of Transmitted HIV-Drug Resistance: More Than Meets the Eye

Despite the use of genotype results to select “fully active” initial treatment regimens, patients with transmitted drug resistance were more likely to experience virologic failure than those without such resistance.

Failure of antiretroviral therapy (ART) often results in genetic changes in the virus that confer resistance to certain antiretroviral drugs. These resistance mutations can be transmitted when new infections occur and can significantly reduce the likelihood of treatment success. Consequently, current guidelines recommend that all patients undergo genotypic resistance testing before starting ART. The effect of transmitted drug resistance–associated mutations (TDRM) on treatment response is most obvious with mutations that change susceptibility to specific drugs. Whether the presence of TDRM also affects treatment outcomes more broadly has not been well studied.

Investigators reviewed pretreatment genotypic testing results from 801 HIV-infecte…

Reviewing Author

Charles B. Hicks, MD

Disclosures

Consultant / Advisory boardGilead Sciences; ViiV; Merck

RoyaltiesUpToDate, Inc.

Grant / Research supportNIH; Department of Health and Human Services

Charles B. Hicks, MD

Disclosures

Consultant / Advisory boardGilead Sciences; ViiV; Merck

RoyaltiesUpToDate, Inc.

Grant / Research supportNIH; Department of Health and Human Services

The Clinical Consequences of Transmitted HIV-Drug Resistance: More Than Meets the Eye

Topics

Reviewing Author